A Phase 2B double-blind, randomized, placebo-controlled, multisite dose-ranging study to assess the efficacy, safety, pharmacokinetics and the optimal dose of bumetanide in children and adolescents with autism spectrum disorder.

Trial Profile

A Phase 2B double-blind, randomized, placebo-controlled, multisite dose-ranging study to assess the efficacy, safety, pharmacokinetics and the optimal dose of bumetanide in children and adolescents with autism spectrum disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Bumetanide (Primary)
  • Indications Pervasive child development disorders
  • Focus Therapeutic Use
  • Sponsors Neurochlore
  • Most Recent Events

    • 22 Mar 2017 New trial record
    • 14 Mar 2017 Results published in the Translational Psychiatry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top